In most of the remaining ET and PMF patients without mutated JAK2 or MPL, a spectrum of mutations within the Calreticulin (CALR) gene has been identified and is found in 25% of ET and PMF patients [8,9]. The gene discussed is JAK2; the disease is essential thrombocythemia.